Scarica l'app Stockscreener
21.89
1.53%
0.33
Dopo l'orario di chiusura:
21.89
Precedente Chiudi:
$21.56
Aprire:
$22.035
Volume 24 ore:
191.65K
Relative Volume:
0.60
Capitalizzazione di mercato:
$748.91M
Reddito:
-
Utile/perdita netta:
$-81.05M
Rapporto P/E:
-8.3448
EPS:
-2.6232
Flusso di cassa netto:
$-68.97M
1 W Prestazione:
-0.05%
1M Prestazione:
-3.99%
6M Prestazione:
-19.67%
1 anno Prestazione:
+7.15%
Intervallo 1D:
$21.68
$22.10
Intervallo di 1 settimana:
$21.10
$23.38
Portata 52W:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Nome
Arrivent Biopharma Inc
Settore
Industria
Telefono
240-780-6356
Indirizzo
18 CAMPUS BLVD., NEWTOWN SQUARE
Confronta AVBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
21.89 | 791.15M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-03-20 | Iniziato | B. Riley Securities | Buy |
| 2025-03-10 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Oppenheimer | Outperform |
| 2024-04-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-20 | Iniziato | Citigroup | Buy |
| 2024-02-20 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | Jefferies | Buy |
Mostra tutto
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
ArriVent BioPharma Eyes Early 2026 for Phase 3 Lung Cancer Drug Data - MyChesCo
ArriVent BioPharma Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Is ArriVent BioPharma Inc. a good long term investmentOverwhelming financial success - jammulinksnews.com
ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
What drives ArriVent BioPharma Inc. stock priceAccelerated wealth expansion - jammulinksnews.com
What analysts say about ArriVent BioPharma Inc. stockFree AI-Backed Trading Signals - jammulinksnews.com
What makes ArriVent BioPharma Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating By Investing.com - Investing.com UK
ArriVent Biopharma announces data from its FURVENT Phase 3 study - TipRanks
ArriVent expects topline data from lung cancer drug trial in early 2026 By Investing.com - Investing.com South Africa
ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - The Manila Times
New Strong Sell Stocks For July 21st - Barchart.com
New Strong Sell Stocks for July 21st - The Globe and Mail
Is ArriVent BioPharma Inc. stock a growth or value playDaily Price Surge List - Newser
P 500Low Risk Trade Timing Signals - Newser
60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest
Why ArriVent BioPharma Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
ArriVent BioPharma Conducts $75 Million Public Offering - Global Legal Chronicle
ArriVent BioPharma (NASDAQ:AVBP) Given a $33.00 Price Target by The Goldman Sachs Group Analysts - Defense World
The Goldman Sachs Group Reiterates “Buy” Rating for ArriVent BioPharma (NASDAQ:AVBP) - Defense World
How To Trade (AVBP) - news.stocktradersdaily.com
ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs - Investing.com Canada
Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz
ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval - Investing.com Canada
ArriVent BioPharma Announces $75 Million Public Offering - The Globe and Mail
Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants - Latham & Watkins LLP
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
ArriVent BioPharma Plans $75 Million Public Offering - MarketScreener
ArriVent BioPharma announces $75 million public offering By Investing.com - Investing.com UK
ArriVent BioPharma's $75M Offering: Navigating Dilution for Oncology's Next Breakthrough - AInvest
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Buy” by Brokerages - Defense World
Research Analysts Offer Predictions for AVBP FY2025 Earnings - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Given Buy Rating at Guggenheim - Defense World
Latest Analyst Updates: June 24th, 2025 - The Globe and Mail
Clear Street initiates ArriVent BioPharma stock with Buy rating By Investing.com - Investing.com Canada
Citi ups ArriVent price target to $40, adding ‘upside 90-day short-term view’ - TipRanks
ArriVent BioPharma (AVBP) Presents Promising Firmonertinib Data in Lung Cancer Study | AVBP Stock News - GuruFocus
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - The Manila Times
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - The Manila Times
ArriVent to Unveil Next Steps for Breakthrough EGFR PACC Lung Cancer Drug Firmonertinib - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases New Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Arrivent Biopharma Inc Azioni (AVBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):